Major depressive disorder (MDD) is associated with reduced concentrations of 3-aminobutyric acid (GABA) that are normalized by antidepressant therapies. Moreover, depressive-like phenotypes of GABA A receptor mutant mice can be reversed by treatment with conventional antidepressants drugs, as well as by subanesthetic doses of ketamine. Thus GABAergic deficits may causally contribute to depressive disorders, while antidepressant therapies may enhance GABAergic synaptic transmission. Here we tested the hypothesis that sustained enhancement of GABAergic transmission alone is sufficient to elicit antidepressant-like behavior, using disinhibition of GABAergic interneurons. We focused on somatostatin-positive (SST +) GABAergic interneurons because of evidence that their function is compromised in MDD. To disinhibit SST + interneurons, we inactivated the 32 subunit gene of GABA A receptors selectively in these neurons (SSTCre:32 f/f mice). Loss of inhibitory synaptic input resulted in increased excitability of SST + interneurons. In turn, pyramidal cell targets of SST + neurons showed an increased frequency of spontaneous inhibitory postsynaptic currents. The behavior of SSTCre: 32 f/f mice mimicked the effects of anxiolytic and antidepressant drugs in a number of behavioral tests, without affecting performance in a spatial learning- and memory-dependent task. Finally, brain extracts of SSTCre: 32 f/f mice showed decreased phosphorylation of the eukaryotic elongation factor eEF2, reminiscent of the effects of ketamine. Importantly, these effects occurred without altered activity of the mammalian target of rapamycin pathway nor did they involve altered expression of SST. However, they were associated with reduced Ca 2+ /calmodulin-dependent auto-phosphorylation of eEF2 kinase, which controls the activity of eEF2 as its single target. Thus enhancing GABAergic inhibitory synaptic inputs from SST + interneurons to pyramidal cells and corresponding chronic reductions in the synaptic excitation:inhibition ratio represents a novel strategy for antidepressant therapies that reproduces behavioral and biochemical end points of rapidly acting antidepressants.
All Science Journal Classification (ASJC) codes
- Molecular Biology
- Psychiatry and Mental health
- Cellular and Molecular Neuroscience